British scientists are infecting a group of volunteers with a type of malaria that can cause relapses years after contracting ...

The following is a summary of “Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical ...

ON 18 December, 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency, ...

cGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia dCentre for Tropical Medicine and Global Health, Nuffield Department of ...

“The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 ...

The Company’s press release highlighted that recently published case reports in medical literature have indicated a high cure rate when tafenoquine is combined with standard-of-care treatment ...

Expert Rev Anti Infect Ther. 2012;10(2):153-165. Some antimalarials have proven antiretroviral activity, such as chloroquine, MQ and primaquine (reviewed in [134]) but no sound population-based ...

(NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the first patient has ...

(SXTPW), a pharmaceutical company specializing in infectious disease treatments, on Wednesday announced the expansion of its clinical trial for tafenoquine, a potential treatment for babesiosis ...

60 Degrees Pharmaceuticals (SXTP) announced that the first patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating ...